RPHM vs. CELU, ANVS, IMMX, CALC, AEON, ELDN, CKPT, KZR, EGRX, and BLRX
Should you be buying Reneo Pharmaceuticals stock or one of its competitors? The main competitors of Reneo Pharmaceuticals include Celularity (CELU), Annovis Bio (ANVS), Immix Biopharma (IMMX), CalciMedica (CALC), AEON Biopharma (AEON), Eledon Pharmaceuticals (ELDN), Checkpoint Therapeutics (CKPT), Kezar Life Sciences (KZR), Eagle Pharmaceuticals (EGRX), and BioLineRx (BLRX). These companies are all part of the "pharmaceutical preparations" industry.
Celularity (NASDAQ:CELU) and Reneo Pharmaceuticals (NASDAQ:RPHM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.
Reneo Pharmaceuticals received 12 more outperform votes than Celularity when rated by MarketBeat users. Likewise, 57.14% of users gave Reneo Pharmaceuticals an outperform vote while only 42.11% of users gave Celularity an outperform vote.
19.0% of Celularity shares are held by institutional investors. Comparatively, 91.0% of Reneo Pharmaceuticals shares are held by institutional investors. 20.7% of Celularity shares are held by insiders. Comparatively, 17.9% of Reneo Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Reneo Pharmaceuticals has a consensus price target of $11.01, suggesting a potential upside of 536.56%. Given Celularity's higher probable upside, analysts clearly believe Reneo Pharmaceuticals is more favorable than Celularity.
Reneo Pharmaceuticals has a net margin of 0.00% compared to Reneo Pharmaceuticals' net margin of -1,226.72%. Reneo Pharmaceuticals' return on equity of 30.79% beat Celularity's return on equity.
Celularity has higher revenue and earnings than Reneo Pharmaceuticals.
Celularity has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500. Comparatively, Reneo Pharmaceuticals has a beta of 0.22, meaning that its stock price is 78% less volatile than the S&P 500.
In the previous week, Reneo Pharmaceuticals had 13 more articles in the media than Celularity. MarketBeat recorded 14 mentions for Reneo Pharmaceuticals and 1 mentions for Celularity. Reneo Pharmaceuticals' average media sentiment score of 0.97 beat Celularity's score of 0.38 indicating that Celularity is being referred to more favorably in the media.
Summary
Celularity beats Reneo Pharmaceuticals on 7 of the 13 factors compared between the two stocks.
Get Reneo Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for RPHM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RPHM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Reneo Pharmaceuticals Competitors List
Related Companies and Tools
